[Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women]
Imaz I, Rubio B, Lopez-Delgado ME, Amate JM, Gomez-Pajuelo P, Gonzalez-Enriquez J
Record ID 32011000304
English, Spanish
Authors' objectives:
To assess cost-utility of the most employed pharmacological treatments in Spain for the prevention of bone fractures in osteoporotic post-menopausal Spanish women.
Authors' recommendations:
In comparison with calcium and vitamin D, or placebo, treating with alendronate, risedronate, ibandronate, raloxifene or strontium ranelate is not efficient for the prevention of bone fractures in osteoporotic post-menopausal Spanish women when they start treatment before the age of 69. However, if women start treatment at an age of 69 or above, alendronate would be efficient.
Details
Project Status:
Completed
URL for project:
http://www.isciii.es/htdocs/publicaciones/documentos/63_Osteoporosis_Coste_utilidad_farmacos.pdf
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Cost-Benefit Analysis
- Female
- Fractures, Bone
- Osteoporosis, Postmenopausal
Contact
Organisation Name:
Agencia de Evaluacion de Tecnologias Sanitarias
Contact Address:
Instituto de Salud "Carlos III", Calle Sinesio Delgado 6, Pabellon 4, 28029 Madrid, Spain. Tel: +34 9 1 822 2005; Fax: +34 9 1 387 7841;
Contact Name:
Luis M. Sánchez Gómez
Contact Email:
luism.sanchez@isciii.es
Copyright:
Agencia de Evaluacion de Tecnologias Sanitarias (AETS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.